Thermo Fisher Scientific TMO

Thermo Fisher Scientific Inc. is advancing its position in the life sciences sector by acquiring The Binding Site Group for £2.25 billion ($2.6 billion), aimed at enhancing its specialty diagnostics portfolio in allergy and autoimmune disease testing. This strategic move follows a series of major acquisitions, including PPD for $20 billion and PeproTech for $1.85 billion, despite a recent decline in earnings. The deal, expected to close in the first half of 2023, is projected to positively impact earnings per share by $0.07 in its first year, reflecting Thermo Fisher's commitment to robust growth amidst market fluctuations.